| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 |
| filingDate |
2006-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49409e38dea13f9d4cdcce4b47fc0e71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b74ec21db53d1faa2fcd79e38b2aa20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_174c3d8236e0fc71e10f21285b3ae670 |
| publicationDate |
2007-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2007123534-A1 |
| titleOfInvention |
Pyrrolotriazine kinase inhibitors |
| abstract |
In general, the instant invention comprises compounds having Formulae I and II: n nincluding pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8471005-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015034213-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9815840-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011052583-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7851489-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008114033-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012065161-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8569319-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8536200-B2 |
| priorityDate |
2005-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |